New York is currently home to 4443 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Recruiting
Multiple myeloma (MM) is a malignancy characterized by uncontrolled proliferation of plasma cells for which there is an urgent and unmet need to develop new, effective therapeutics. Onconova Therapeutics has developed a first-in-class oral inhibitor of CDK4 and ARK5 ON 123300 (NARAZACICLIB) which shows potent anti-myeloma activity in vitro and in vivo in preclinical models, and is undergoing evaluation in Phase 1-2 trials worldwide. In this study, the researchers will test the safety and prelim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Mount Sinai Health System, New York, New York
Conditions: Relapsed and/or Refractory Multiple Myeloma
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/01/2024
Locations: NYU Langone Medical Center, New York, New York
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation
Recruiting
The purpose of the study is to explore options for preventing and reducing symptoms of radiation esophagitis (RE). The researchers will also look what symptoms participants experience, and whether there are differences in weight loss in participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ), Commack, New York
Conditions: Radiation Esophagitis
Cannabidiol as a Treatment for Social Anxiety Disorder (R61)
Recruiting
The R61 will include two CBD dose levels vs placebo (PBO) and examine potential engagement with two primary targets in a 3-week randomized controlled trial design. Willing and eligible subjects will be randomized to one of three randomized double-blind treatments (n = 20 each group): 1) CBD 800 mg (400 mg twice daily), 2) CBD 400 mg (200 mg twice daily), or 3) PBO twice daily for three weeks. Participation is estimated at approximately 1 month from end of screening to endpoint for the primary R... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
10/01/2024
Locations: NYU Langone Health, New York, New York
Conditions: Social Anxiety Disorder
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York
Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
Recruiting
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: OP-1250 in combination with everolimus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Ichan School of Medicine at Mount Sinai, New York, New York
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Breast Cancer
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Brooklyn VA Medical Center, Brooklyn, New York
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
A Study of Repotrectinib in Combination with Chemotherapy in Children and Young Adults with Solid Tumor Cancer
Recruiting
This study will test the safety of the study drug, repotrectinib, in combination with chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or metastatic solid tumors. We researchers will try to find the highest dose of the study drug that causes few or mild side effects in study participants. When the researchers find this dose, we will evaluate it in a different group of participants to find out whether repotrectinib in combination with chemotherapy is an ef... Read More
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
10/01/2024
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Advanced Cancer, Metastatic Solid Tumor
SMR Stemless Reverse Vs SMR Reverse Shoulder System
Recruiting
The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function. This is a prospective, multi-center, randomized, controlled trial to demonstrate non-inferiority of the SMR Stemless Reverse to the SMR Reverse Shoulder System. Patients with joint dysfunction who continue to experience significant symptoms despite an appropriate course of non-operative management are eligible. Patients will be considered enroll... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
10/01/2024
Locations: Upstate Orthopedics, East Syracuse, New York
Conditions: Arthroplasty, Replacement
Molecular Genetics Studies of Cancer Patients and Their Relatives
Recruiting
This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.
Gender:
ALL
Ages:
All
Trial Updated:
10/01/2024
Locations: Mount Kisco Medical Group at Northern Westchester Hospital, Mount Kisco, New York
Conditions: Malignant Neoplasm
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Recruiting
The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring. WeThe reserchers are doing this study to see whether this advanced imaging is a safe treatment that causes few or mild side effects in people with brain tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Brain Cancer, Glioma
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People with Hairy Cell Leukemia (HCL)
Recruiting
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities), Commack, New York
Conditions: Hairy Cell Leukemia